Immunotherapeutic options for management of metastatic cervical cancer

• DOI: 10.21518/ms2023-446
• Publication Date: 2024-01-19T06:34:36Z
• Authors: K. V. Menshikov; A. V. Sultanbaev; Sh. I. Musin; I. A. Menshikovа; N. I. Sultanbaeva; A. V. Chashchin; D. О. Lipatov; A. A. Izmailov
• Keywords: Carboplatin; Regimen

Cervical cancer (CC) remains one of the common tumour diseases women. It accounts for 9.8% all neoplasia in The Food and Drug Administration approved pembrolizumab with PD-1 inhibitor antibodies treatment RSM following KEYNOTE-158 clinical trial. PD-L1/PD-1 inhibitors have shown promising results against objective response rate female patients CC. A case a patient metastatic CC progression after radiotherapy pelvic organ evisceration is described. underwent IHC examination material was found to PDL1 expression more than 1% according 22C3 antibody assay. According instructions Pembroria® it decided start systemic chemotherapy regimen paclitaxel 175 mg/m 2 , carboplatin AUC5 at dose 200 mg every three weeks. After third course, control MRI study performed. partial iRECIST criteria confirmed. sixth course therapy cytostatics were cancelled, continued monotherapy once At 10 months therapy, conglomerate right hindbrain fossa not detected complete In given observation anti-PD1 allowed achieve remission disease. Thus, demonstrates efficacy advanced